ACTICOR Adapts Its ACTISAVE Clinical Study to Prepare the Registration of Glenzocimab for the Treatm
- Clinical results from ACTISAVE phase 2/3 study now expected in the second quarter of 2024- Optimised development plan to register glenzocimab in Europe and the United States projected no later than 2028PARIS--(BUSINESS WIRE)--Regulatory News:Acticor Biotech, (ISIN: FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical s...